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ABSTRACT
Background The symptoms, radiography, biochemistry 
and healthcare utilisation of patients with COVID-19 
following discharge from hospital have not been well 
described.
Methods Retrospective analysis of 401 adult patients 
attending a clinic following an index hospital admission 
or emergency department attendance with COVID-19. 
Regression models were used to assess the association 
between characteristics and persistent abnormal chest 
radiographs or breathlessness.
Results 75.1% of patients were symptomatic at a median 
of 53 days post discharge and 72 days after symptom 
onset and chest radiographs were abnormal in 47.4%. 
Symptoms and radiographic abnormalities were similar 
in PCR- positive and PCR- negative patients. Severity of 
COVID-19 was significantly associated with persistent 
radiographic abnormalities and breathlessness. 18.5% of 
patients had unscheduled healthcare visits in the 30 days 
post discharge.
Conclusions Patients with COVID-19 experience 
persistent symptoms and abnormal blood biomarkers with 
a gradual resolution of radiological abnormalities over time. 
These findings can inform patients and clinicians about 
expected recovery times and plan services for follow- up of 
patients with COVID-19.
INTRODUCTION
Since initial detection of SARS- CoV-2 almost 
110 million cases of COVID-19 have been 
confirmed worldwide, with an estimated 
global death toll of almost 2.4 million.1 
Patients with more severe disease require 
hospitalisation and large numbers of patients 
have survived and been discharged from 
hospital. The clinical features of hospital-
ised patients with COVID-19 have been well 
described2; however, less data are available on 
the recovery period of patients after discharge. 
The symptomatic and radiographic recovery 
times, risk of short- term complications, 
optimal timing of follow- up and prevalence 
of long- term sequelae are still uncertain. The 
studies of recovered patients that are avail-
able have described a prolonged burden of 
symptoms following hospital discharge.3–9 
However, some features of recovery which 
are less well characterised include the rate 
of recovery of symptoms, recovery in non- 
hospitalised patients and patients without a 
positive PCR swab, biochemical and haema-
tological recovery and healthcare utilisation.
We collected symptomatic, radiographic, 
biochemical and healthcare utilisation data 
from patients with COVID-19 who attended a 
follow- up clinic after discharge from hospital. 
We describe the recovery times for these 
parameters, examined the factors associated 
with symptomatic and radiographic recovery 
and recorded unscheduled healthcare use in 
these patients.
Key messages
 ► How quickly do the symptoms, radiography and bio-
chemistry of patients with COVID-19 who had been 
admitted to hospital or attended the emergency de-
partment take to resolve, and how frequently do they 
access healthcare?
 ► The majority of patients with COVID-19 are still 
symptomatic at a median of 53 days post discharge 
and 72 days after symptom onset and 18.5% of pa-
tients had unscheduled healthcare visits in the 30 
days post discharge.
 ► These data provide a further description of the re-
covery period following COVID-19 infection.
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METHODS
Study design and participants
This retrospective cohort study collected data from 
adult patients who attended a COVID-19 follow- up clinic 
between 1 May 2020 and 21 July 2020. Patients who had 
either been admitted to, or attended the emergency 
departments (ED) of the three acute hospitals of Impe-
rial College Healthcare NHS Trust (ICHNT) between 21 
March 2020 and 13 June 2020 were identified. ICHNT is 
one of the largest NHS Trusts in London that provides 
care for an urban population in North West London. 
Patients were identified either on the basis of a positive 
SARS- CoV-2 PCR test, or a clinical diagnosis of COVID-19 
with a negative PCR (or no swab taken) if they had typical 
clinical, radiological and biochemical features consistent 
with COVID-19 as assessed by a consultant physician and 
had been treated as COVID-19. Patients were invited 
to attend the clinic but patients who were judged to be 
too frail to attend or who lived outside the area were 
excluded. Five patients acquired coronavirus infection 
while in hospital and were not included in the illness 
duration and length of stay (LOS) analyses. The project 
was registered with the audit team under the Directorate 
of Acute and Specialist Medicine ICHNT (registration 
number 488).
Patient and public involvement
Patients and the public were not involved in the design 
and conduct of this project.
Identification of patient variables
Relevant data were extracted from patient hospital 
records. Data collected from the first patient encounter 
included information on: demographics, comorbid-
ities, frailty score10 and The National Early Warning 
Score 2 (NEWS2).11 Admission chest radiographs were 
reported by FRCR certified Trust radiologists using 
the British Society of Thoracic Imaging (BSTI)/NHS 
England (NHSE) endorsed validated reporting template 
(normal, classic/probable COVID-19, indeterminate 
and non- COVID-19) and the severity score recorded 
(mild, moderate and severe).12 13 Blood test results were 
recorded, including C reactive protein (CRP, normal 
value <5 mg/L), ferritin (normal value <300 mg/L), 
D- dimer (normal value <500 mg/L), troponin (normal 
value <5 mg/L) and blood lymphocyte count (normal 
value >1×109/L).
For hospitalised patients, details were collected on LOS, 
maximal inspired fraction of oxygen (FiO2) required 
(room air, ≤0.4, >0.4), history of intubation and inpa-
tient investigations for venous thromboembolism (VTE). 
Where chest radiographs and blood tests were repeated, 
the most abnormal result was recorded.
A standard proforma was used to record symp-
toms (cough, breathlessness, chest pain and fatigue) 
and unscheduled healthcare visits in the 30 days post 
discharge. Patients were asked to estimate their exercise 
tolerance prior to hospital admission and currently, using 
the Medical Research Council (MRC) questionnaire,14 
and the presence of ongoing psychological trauma 
assessed using a standardised tool.15 A sit- to- stand test was 
carried out to detect exercise- induced desaturation (a 
fall in oxygen saturation of ≥4%)16 and chest radiographs 
and blood tests carried out. Chest radiographs were 
reported by FRCR certified Trust radiologists and were 
defined as resolved (if normal or had returned to base-
line), significantly improved, not significantly improved 
or worse using BSTI radiographic follow- up of COVID-19 
reporting templates.17 BSTI reporting templates with 
codes were embedded into the radiology information 
system to facilitate consistency of reporting and allow 
categorisation of radiographic appearances. Reporting 
template training for radiologists was performed by 
subspeciality thoracic radiologists.
Statistical analysis
Continuous and categorical variables were presented as 
median (IQR) and number (%), respectively. Patients 
were classified according to the level of care received: ‘ED 
only’ patients attended the ED but were not admitted to 
hospital; ‘Level I’ patients were admitted and required 
ward- based level of care; ‘Level II/III’ patients were 
admitted and required either invasive or non- invasive 
ventilatory support. To analyse the relationships between 
time between hospital discharge and clinic review, Level 
I patients were divided into patient seen <42 days (Early), 
between 42 and 56 days (Intermediate) and >56 days post 
discharge (Late).
Logistic regression models were conducted, using 
complete case analysis, to measure any association between 
a patient’s clinical characteristics during admission and any 
(1) persistent radiological abnormalities, or (2) breathless-
ness, at follow- up. Model covariates included clinically rele-
vant explanatory variables identified a priori: age, gender, 
socioeconomic status, NEWS2, CRP, lymphocyte count, 
admission radiograph severity, maximal oxygen require-
ment, intubation and time from discharge to follow- up. 
Analyses were performed using R V.3.4.
RESULTS
Patient demographics
Four hundred one patients attended the clinic and were 
included in the final analysis (table 1). Median age was 59 
years, 76.3% had a positive SARS- CoV-2 PCR test, 59.6% 
of patients were male, median Rockwood frailty score was 
1 (IQR 1–3), 15.5% worked in the health or social care 
sectors, 81% had a body mass index ≥25% and 61.8% were 
of black, Asian and minority ethnic origin. Most patients 
(315, 78.5%) were in the Level I group; 38 (9.5%) were 
Level II/III (32 intubated) and 48 (12%) patients were 
in the ED- only group. Patients with a positive PCR had 
higher oxygen requirements compared with PCR- negative 
patients, but otherwise there were no differences in their 
demographics or disease severity markers.
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Hospital admission/ED attendance characteristics
The characteristics of the index hospital admission or ED 
attendance are shown in table 2. The median duration of 
symptoms prior to admission was 8 days and the median 
LOS was 5 days. Three hundred one (75.5%) patients 
had mild–moderate disease based on assessment of chest 
radiograph and 310 (77.3%) required a maximum FiO2 
≤0.4. Forty- nine (12.2%) patients were investigated for 
VTE in hospital of which 13 (3.3%) were positive.
Clinic data
The median time from discharge until clinic appoint-
ment was 53 days (IQR 36–67) and the median time from 
symptom onset was 72 days (IQR 55.75–89) (table 3). 
Seventy- five per cent of patients were still experiencing 
symptoms at follow- up: 46.4% reported breathlessness, 
45.1% fatigue, 30.5% cough and 23.8% chest pain. 
Among symptomatic patients, 63.1% experienced at least 
two symptoms. Level II patients were most likely to be 
symptomatic (89.5%) and those in the ED only group 
were least likely to be symptomatic (70.8%). 40.8% of 
patients reported not returning to their preillness exer-
cise tolerance level, and MRC score was significantly 
higher than preadmission scores (baseline median 
MRC=1, clinic median MRC=2, p<0.0001). 13.1% of 
patients desaturated on the sit- to- stand test and 15% of 
patients scored positive for psychological distress related 
to their hospital admission. 47.4% (126/309) of patients 
had an abnormal chest radiograph. Twenty- one per cent 
had a high CRP, 16.7% had a high ferritin and 34.8% had 
a high D- dimer level. There were no differences between 
patients with a positive PCR and those with a clinical diag-
nosis, other than a higher prevalence of elevated D- dimer 
in PCR- positive patients (table 4).
Healthcare utilisation post discharge
Seventy- four patients (18.5%) had COVID-19 related 
unscheduled healthcare visits (to primary or secondary 
care). These visits resulted in 12 CT pulmonary angio-
grams (CTPAs) (including two diagnoses of pulmonary 
embolism (PE)), 2 thoracic CT scans and 8 chest radio-
graphs. A further 18 patients had investigations for VTE 
from the clinic with 1 CTPA positive for a previously undi-
agnosed chronic PE.
Relationships between time from discharge and recovery
Among the Level II patients, 109 (35.0%) were seen 
<42 days from discharge, 79 (25.3%) at 42–56 days and 
124 (39.7%) at >56 days post discharge (table 5). There 
was no difference in the proportion of patients reporting 
symptoms between the different time points (p=0.38). 



















59.0 (21–95) 54.0 (23–84) 61.0 (21–95) 52.5 (30–80)
BMI (n=381)         
  <18 4 (1%) 1 (2.2%) 3 (1%) 0 (0%)
  18.5–24.9 69 (18%) 9 (19.6%) 55 (18.5%) 5 (14%)
  25–29.9 149 (39%) 16 (34.8%) 119 (40%) 14 (39%)
  30–39.9 136 (36%) 14 (30.4%) 105 (35%) 16 (44.4%)
  >40 23 (6%) 6 (13%) 16 (5.5%) 1 (2.6%)
Comorbidities         
  Any 324 (81%) 35 (73%) 266 (84.4%) 23 (60.5%)
  Diabetes mellitus 112 (27.9%) 6 (12.5) 99 (31.4%) 7 (18.4%)
  Hypertension 168 (42%) 15 (31.25%) 142 (45%) 11 (29%)
  CVS 74 (18.5%) 8 (16.7%) 62 (19.7%) 4 (10.5%)
  Cancer 31 (7.7%) 3 (6.35%) 25 (7.9%) 1 (2.6%)
  Asthma 61 (15.2%) 10 (20.8%) 48 (15.2%) 3 (8%)
  COPD 20 (5%) 2 (4.2%) 17 (5.4%) 1 (2.6%)
BAME background
(n=372)
227/372 (61%) 29/43 (67.4%) 172/292 (58.9%) 27/38 (71.1%)
Smoking (n=360)
Current/ex/never
10/91/263 3/7/31 7/75/219 2000/9/24
BAME, black, Asian and minority ethnic; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVS, cardiovascular disease.
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Significantly more patients in the Early group had cough 
compared with the Late group (Early 48.8%, Late 32.7%; 
p=0.02), breathlessness was most common in the Inter-
mediate group (Early 44.1%, Intermediate 71.9%, Late 
53%; p=0.0047), and fatigue was more common in the 
Late group (Early 48.8%, Intermediate 59.7%, Late 
73.3%, p=0.004). The prevalence of abnormal chest radi-
ographs fell significantly with increased length of time 
from hospital discharge (Early 66.4%, Intermediate 48%, 
Late 29.5%; p<0.0001; table 5). There was no difference 
in the prevalence of high CRP between the time points 
but elevated ferritin and D- dimers were less prevalent in 
the Late group compared with the Early group.
Factors associated with breathlessness and abnormal chest 
radiograph at follow-up
Longer time to clinic was associated with significantly 
lower odds of an abnormal chest radiograph: Inter-
mediate and Late groups had 0.37 (95% CI 0.20 to 
0.68) and 0.17 (95% CI 0.09 to 0.30) fold lower odds 
of abnormalities, compared with the Early group. 
Controlling for other parameters, patients aged above 
60 years and above 80 years had 8.4 (95% CI 2.71 to 
28.6) and 4.6 (95% CI 1.17 to 19.0) fold higher odds of 
abnormal chest radiograph compared with those aged 
20–40 years, respectively. Patients with greater severity 
of illness (CRP, NEWS2, lymphocyte count, chest radio-
graph severity, oxygen requirement, intubation) during 
admission were more likely to have an abnormal chest 
radiograph on follow- up. Controlling for other parame-
ters, patients with moderate or severe chest radiograph 
score during hospital admission had 2.13 (1.19–3.85) and 
3.28 (1.59–6.90) fold higher odds of abnormal chest radi-
ograph at follow- up, compared with those with mild chest 
radiograph score. Similarly, patients who had maximal 
FiO2 >0.4 during admission had 3.36 (1.17–9.94) times 
higher odds of an abnormal chest radiograph compared 
with those requiring room air only. Intubation was not 
independently associated with resolution of chest radio-
graph changes (adjusted OR=0.745; 95% CI 0.24 to 2.34).










Time to clinic from discharge (days)
Median (IQR)
53 (36–67) 82.5 (65.25–93.5) 50.5 (35–61) 43 (32–51.25)
Time to clinic from illness onset (days)
Median (IQR)
72 (55.75–89) 91 (74.75–102.5) 66 (52–82) 84 (69–84.5)
Abnormal chest radiograph 176/390 (45.0%) 8/46 (17.4%) 145/306 (47.4%) 25/38 (65.8%)
Symptoms 301/401 (75.1%) 34/48 (70.8%) 232/315 (73.7%) 34/38 (89.5%)
C reactive protein
Patients>ULN
84/399 (21.0%) 7/47 (14.9%) 68/314 (21.7%) 9/38 (23.7%)
Ferritin
Patients>ULN
66/396 (16.7%) 5/47 (10.6%) 59/311 (19.0%) 2/38 (5.3%)
D- dimer
Patients>ULN
137/394 (34.8%) 10/46 (21.7%) 117/310 (37.7%) 10/38 (26.3%)






Time to clinic from discharge (days)
Median (IQR)
52 (35–61) 56 (40–83) 0.0011
Time to clinic from illness onset (days)
Median (IQR)
71 (54–85) 76 (56.75–94.25) 0.0083
Abnormal chest radiograph 137/306 (44.8%) 39/93 (41.9%) NS
Symptoms 236/307 (76.9%) 67/94 (71.3%) NS
CRP
Patients>ULN
68/305 (22.3%) 12/94 (12.8%) NS
Ferritin
Patients>ULN
50/303 (16.5%) 15/93 (16.1%) NS
D- dimer
Patients>ULN
113/302 (37.4%) 23/92 (25%) 0.03
Healthcare utilisation 59/307 (19.2%) 23/94 (24.5%) NS
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DISCUSSION
We report a prolonged burden of symptoms, persistent 
radiological and biochemical abnormalities and frequent 
unscheduled healthcare visits in patients with COVID-19 
following hospital admission or ED attendance. More 
severe acute illness and increased age were associated 
with persistent chest radiographic abnormality.
The clinical illness caused by the novel coronavirus 
SARS- CoV-2 has been well characterised2; however, the 
recovery period is not as well described. Recovery time 
from pneumonia is influenced by many factors including 
illness severity, age and comorbidities18 but most patients 
with non- COVID pneumonia recover by 10–21 days18–20 
and only 35% have unresolved symptoms at 28 days.21 A 
COVID-19 WHO document states that ‘typically people 
recover from COVID-19 after 2 to 6 weeks’.22
Studies of recovery time have had varying results with 
some reporting that most patients recover by 4 weeks5 
whereas others report most patients are still symptom-
atic at 63 and 86 7 weeks post discharge. Limitations of 
published studies have included small cohorts,5 23 patients 
seen at early postdischarge time points5 8 and lack of data 
on non- hospitalised patients7 8 23 and patients with a clin-
ical COVID-19 diagnosis.6 8 23
Our study provides additional data to the published 
studies as we examined outcomes at different time 
points and recorded time from illness onset; we included 
patients not admitted to hospital and patients with a clin-
ical diagnosis of COVID-19 and we examined factors that 
predict recovery and recorded data on healthcare util-
isation. In keeping with other studies, we report a high 
prevalence of symptoms in patients following hospital 
admission or ED attendance with COVID-19. There was 
no significant difference in the percentage of patients 
reporting symptoms between those seen up to 6 weeks 
and those seen at 8 weeks and beyond. The latter group 
were seen at a median of 85 days from illness onset and 
still 71.8% were symptomatic. Even among patients 
who were not admitted to hospital seen at a median of 
82.5 days from ED attendance and 91 days from illness 
onset, 70.8% were still symptomatic. There was no differ-
ence in reported symptom between PCR- positive and 
PCR- negative patients. Therefore, our study adds to the 
literature describing prolonged symptoms following 
acute COVID-19 infection and extends these observa-
tions to non- hospitalised patients and those with a clin-
ical diagnosis of COVID-19.
The most common residual symptoms were fatigue, 
breathlessness and cough. In non- COVID CAP, breath-
lessness and fatigue resolve on average 25 days and 
cough 13.6 days from symptom onset,15 so recovery from 
COVID-19 appears to be significantly prolonged. The 
prevalence of individual symptoms varied, with cough 
more common earlier in the recovery period while fatigue 
was more prominent later. It is possible that variation may 
relate to underlying pathophysiology, but symptoms may 
be influenced by when patients recommence normal 
levels of activity after discharge, patient expectations 
and ability to exercise during the pandemic- related lock-
down. The subjective nature of symptoms such as breath-
lessness and complex influences on patient experiences 
of this may explain the poor association between disease 








Time to clinic from illness onset (days)
Median (IQR)
48 (35–82) 64 (50–99) 85 (61–133)
Symptomatic patients 86 (78.9%) 58 (73.4%) 89 (71.8%)




  Cough 42 (48.8%) 19 (33.3%) 28 (32.0%)
  Breathlessness 38 (44.2%) 48 (71.9%) 47 (53.3%)
  Chest pain 27 (31.4%) 22 (38.6%) 29 (32.2%)
  Fatigue 42 (48.8%) 35 (59.7%) 65 (73.3%)
Abnormal chest radiograph 71/107 (66.4%) 36/75 (48.0%) 37/121 (29.5%)
CRP 17/108 18/78 20/122
Patients>ULN −15.70% −23.20% −16.40%
Ferritin 28/107 16/78 16/123
Patients>ULN −25% −20.50% −13%
D- dimer 48/107 22/76 47/122
Patients>ULN (45%.0) −29.00% −38.50%
Early follow- up (<42 days); Intermediate follow- up (42–56 days) and Late follow- up (>56 days).
CRP, C reactive protein.
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severity markers and residual breathlessness in our study, 
in comparison to the stronger correlations with objec-
tive chest radiographic abnormality. Further studies are 
needed to understand how and why symptoms change 
during the recovery period. Forty per cent of patients 
had not returned to their baseline exercise capacity 
after discharge. Impaired exercise capacity may in part 
be a result of patients self- isolating and the limitations 
imposed on exercising outside. It remains unclear what 
proportion of patients will experience impaired exercise 
capacity in the longer term, but these patients may place 
a significant burden on rehabilitation services in the 
future. Fifteen per cent of patients had anxiety symptoms 
and the provision of counselling and psychology services 
may need to be expanded to provide for patients with 
COVID-19.
Almost a quarter of patients in our study reported 
chest pain, despite the WHO not currently listing this 
as a COVID-19 symptom. 68.6% of patients hospitalised 
with non- COVID CAP experience chest pain,24 with a 
median time to resolution of 7–9 days.18 The aetiology 
of the chest pain is unclear as investigations such as 
CTPA and cardiac enzymes were negative. There has 
been considerable concern about the occurrence of VTE 
in COVID-19,25 but only one chronic PE was identified 
that likely occurred during the acute phase of COVID-
19. Therefore, these data provide some reassurance that 
VTE risk is not elevated in the postdischarge period 
despite suggestive symptoms and biomarkers, although 
CTPAs can potentially miss subsegmental pulmonary 
emboli and a recent report highlighted the possibility of 
potential undiagnosed myocardial injury in patients with 
COVID-19.26 The threshold at which investigations are 
requested in these patients may need to be raised and 
further studies are needed to understand the pathophys-
iology of persistent symptoms.
There are conflicting data regarding radiographic reso-
lution following COVID-19. A Chinese study reported 
complete radiological resolution on CT scan in 53% 
of 149 hospitalised patients at 3 weeks postdischarge,27 
whereas another Chinese study reported 52% of patients 
had pulmonary fibrosis at 58 days post discharge.28 In 
non- COVID CAP, 53%–68% of chest radiographs are 
normal at 4 weeks post discharge.29 30 In our cohort, 45% 
of chest radiographs were abnormal at follow- up, similar 
to the 38% reported by Mandal et al,6 but higher than 
the 23% reported by Sykes et al.23 There was a clear trend 
towards radiographic resolution with longer time from 
discharge but even in patients seen at >56 days, 29.5% 
of chest radiographs were abnormal, as were 17.4% in 
patients who were not hospitalised. There was a similar 
prevalence of abnormal chest radiographs in PCR- 
positive and PCR- negative patients. Patients with more 
severe acute illness and older patients were more likely 
to have radiographic abnormalities, so radiographic 
resolution will vary across different patient subgroups. 
Our findings of a halving of abnormal chest radiographs 
between the Early and Late time points support the 
British Thoracic Society recommendation that patients 
with COVID-19 should have a follow- up chest radiograph 
at 12 weeks post discharge, rather than the standard 6 
weeks.31 The prevalence of long- term radiological abnor-
malities following COVID-19 remains unknown.
18.5% of patients accessed unscheduled healthcare 
for COVID- related issues after discharge. AUK study 
reported that 40% of COVID- related calls to a specialist 
advice telephone service for primary care physicians 
related to persistent symptoms.31(This is linked to the 
correct reference but it should be 31 not 30) Our data 
should provide reassurance to patients experiencing 
persistent symptoms that the recovery period following 
COVID-19 infection is prolonged and persistent symp-
toms are common. This knowledge should help reduce 
unnecessary investigation; however, more data in larger 
cohorts are needed and symptomatic patients will still 
require careful assessment by clinicians.
Our study has several limitations. We were only able 
to include a select cohort of patients as extremely frail 
patients were not seen, while others declined the invita-
tion to attend. This cohort was from a single centre split 
across three geographical locations but, due to their inner 
city locations, the three hospitals serve a diverse popula-
tion. Symptoms were recorded by asking patients if they 
were present or not, we did not use standardised tools 
to assess symptom severity or quality of life. Chest radio-
graphs were only classified as resolved or not resolved 
and the degree of improvement was not recorded.
In conclusion symptomatic, radiographic and 
biochemical recovery times following COVID-19 infec-
tion are prolonged with older age and more severe acute 
illness associated with non- recovery. Healthcare utilisa-
tion during the recovery period is common. Follow- up of 
patients with COVID-19 has imposed considerable strain 
on healthcare resources that will be further intensified 
following subsequent waves of infection. These results 
should lead to revised advice as to the expected recovery 
time from COVID-19, reduce unscheduled healthcare 
use and investigations, ensure that PCR- negative patients 
and non- hospitalised patients are also followed up and 
aid with planning the appropriate timing of follow- up 
and targeting of high risk patients.
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